Cefoxitin 2g powder for solution for injection vials
Requires a prescription from a doctor or prescriber
Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cefoxitin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cefoxitin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Cefoxitin on the MHRA register
Renoxitin 2g powder for solution for injection vials
WHO defined daily dose (DDD)
6 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Cefoxitin
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
194 found
Half-life
41 to 59 minutes
Mechanism
The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
41 to 59 minutes
Metabolism
6-hour
Elimination
6-hour
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 799 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC J01DC01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cefoxitin
Additional database identifiers
Drugs Product Database (DPD)
11254
ChemSpider
389981
BindingDB
50335563
PDB
CFX
ZINC
ZINC000003830449
GenBank Gene Database
X06480
GenBank Protein Database
41218
UniProt Accession
DACC_ECOLI
GenBank Gene Database
X06479
UniProt Accession
DACA_ECOLI
UniProt Accession
PBP7_ECOLI
GenBank Gene Database
X59460
GenBank Protein Database
41216
UniProt Accession
DACB_ECOLI
GenBank Gene Database
X02164
GenBank Protein Database
581194
UniProt Accession
PBPA_ECOLI
GenBank Gene Database
X02163
GenBank Protein Database
42468
UniProt Accession
PBPB_ECOLI
GenBank Gene Database
K00137
UniProt Accession
FTSI_ECOLI
UniProt Accession
Q75Y35_STREE
GenBank Gene Database
AE007317
GenBank Protein Database
15457529
UniProt Accession
Q7CRA4_STRR6
UniProt Accession
PBP2A_STRR6
GenBank Gene Database
M90527
GenBank Protein Database
153767
UniProt Accession
PBPA_STRR6
GenBank Gene Database
X16022
GenBank Protein Database
984233
UniProt Accession
PBP2_STRR6
GenBank Gene Database
V00093
GenBank Protein Database
39575
UniProt Accession
BLAC_BACLI
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: